Biosynthetic insulin made via recombinant DNA, the first of the class of therapies now known as biologics, was approved in 1982.
Since then, more than 700 biologic therapies (including biosimilars) have been approved for use by the FDA, bringing the value of the U.S. biologics...
Read more »